Tuesday, 28 June, 2022
TopicCovid drug

Topic: Covid drug

WHO recommends two new Covid drugs, in discussions to secure ‘equitable access’

Extent to which Baricitinib & Sotrovimab will save lives depends on how available, affordable they will be, says WHO. New guidelines advise against use of Remdesivir, Ivermectin.

WHO approves Glaxo and Eli Lilly drugs to treat Covid amid Omicron surge

Eli Lilly’s rheumatoid arthritis drug and GlaxoSmithKline's monoclonal antibody won the WHO nod.

Antiviral Molnupiravir not in govt Covid protocol, but ‘millions of doses’ distributed in a week

Pharma companies say doctors working in community settings have begun pre-ordering the drug, several manufacturers gearing up to meet demand.

Scientists launch hunt to find naturally Covid-resistant people, 1,000 volunteers to be enrolled

The study looks for people genetically resistant to SARS-CoV-2 virus — if such natural immunity exists. Candidates are one of a couple, where only one partner fell sick, despite close contact.

ICMR drops Ivermectin, Hydroxychloroquine from clinical guidelines for Covid management

Issuing a set of revised guidelines, ICMR advised that Remedesivir should be used only in select Covid patients and use of Tocilizumab should also be in specific circumstances.

No benefits of Doxycycline found in UK Covid patients, write Oxford researchers in Lancet study

According to researchers, the drug that has been commonly used to treat Covid respiratory symptoms does not reduce recovery time, hospital admissions, or deaths related to Covid.

Has Covid exposed limitations of ‘secretive’ ICMR? Some experts think so

The ICMR has increasingly drawn criticism from India's doctors and scientists, who have questioned its drug recommendations & lack of transparency on data related to variants.

Pharma firms and diagnostics developers need to unite. They are catalysts for saving lives

Studies of drugs like remdesivir and hydroxychloroquine were underpowered and small, and the results were conflicting and, in many cases, inconclusive.

Molnupiravir helps in faster recovery of mild Covid patients, says Hetero after phase 3 trials

Hyderabad-based pharma company, Hetero, announced promising interim results of phase 3 trials and has approached DCGI for emergency use authorisation for the drug in India.

Dr Reddy’s announces commercial launch of Covid drug 2-DG, to cost Rs 990/sachet

The drug was developed by DRDO in collaboration with Dr Reddy's and granted emergency use approval on 1 May. It will be supplied to major govt and private hospitals across India.

On Camera

YourTurn

J.P.Singh, joint secretary (Pakistan, Afghanistan and Iran Division), MEA, meets Taliban's interim foreign minister Amir Khan Mottaki | Photo credit: Twitter/@QaharBalkhi

Hard-nosed, practical—why India has revived relations with Kabul, and why Taliban is welcoming

By protecting the Indian embassy in Kabul for the last ten months, the Taliban is sending a message to its neighbours and the rest of the world.
An employee works at Mahindra & Mahindra Ltd. facility in Chakan, Maharashtra | Bloomberg file photo

Bigger cars, smaller chips — Why Mahindra is worried about increased wait time

A major focus for Mahindra will be defending its market share in the large-format SUV segment from Tata Motors and Hyundai Motor.

Defence

The Indian Air Force logo | Commons

Almost 4,000 enrol for IAF’s Agnipath recruitment scheme on day 1 of online registrations

These registrations pertain to the Indian Air Force's Agniveer Vayu programme. The online portal for the first phase was opened at 10 am Friday, and will close on 5 July.

With Agnipath, Modi govt’s shock & awe doctrine may have misfired a vital reform, yet again

Modi govt's biggest flaw has been its disinclination to accept limitations of electoral majorities. This ruined land acquisition and farm reform, stalled labour codes.
×